Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03092934
Other study ID # 17228
Secondary ID AURA-001J1O-MC-J
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date May 29, 2017
Est. completion date April 20, 2020

Study information

Verified date June 2021
Source Eli Lilly and Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This two-part study consists of a phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a phase 2 portion in up to 3 groups with either small cell lung cancer, breast cancer and/or one other solid tumor type.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date April 20, 2020
Est. primary completion date April 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have received at least 1 but no more than 4 prior systemic therapies - Have adequate organ function - Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale - Have estimated life expectancy greater than or equal to (=)12 weeks - Have fully recovered from radiation therapy or surgery, and are recovering from any acute adverse effects of other cancer therapies - Have discontinued all chemotherapy, investigational therapy, molecularly-targeted therapy, and cancer-related hormonal therapy at least 14 days prior, biologic or immunotherapeutic therapy at least 21 days prior, or mitomycin-C or nitrosoureas at least 6 weeks prior - Female participants with reproductive potential agree to use 2 forms of highly effective contraception during the study and for the following 3 months - Male participants must use a barrier method of contraception during the study and for the following 3 months Phase 1 - Have evidence of a solid tumor that is locally advanced and/or metastatic (excluding primary brain tumor) Phase 2 - Have disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 - Have evidence of a solid tumor that is locally advanced and/or metastatic, and in: - Small Cell Lung Cancer (SCLC), must have failed platinum-containing therapy - Breast Cancer, be Estrogen Receptor positive and/or Progesterone Receptor positive, but Human Epidermal Growth Factor Receptor 2 (HER2) negative, and must have failed a hormone therapy and a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor - Triple negative breast cancer (TNBC) and failed standard therapy - Squamous cell cancers of the head neck associated with the human papilloma virus (HPV), and have failed standard therapy - Other solid tumor type that has been approved by the sponsor Exclusion Criteria: - Have symptomatic central nervous system (CNS) metastasis (unless asymptomatic and not current receiving corticosteroids) or a primary tumor of the CNS - Have a medical condition that precludes participation (swallowing disorder, organ transplant, pregnant or nursing, HIV, active Hepatitis B or C, cardiac disease, history of major surgery in upper gastrointestinal (GI) tract or GI disease, hypokalemia, hypomagnesaemia or hypocalcaemia that cannot be controlled)

Study Design


Intervention

Drug:
LY3295668
Oral capsules

Locations

Country Name City State
Canada Cross Cancer Institute Edmonton Alberta
Canada Jewish General Hospital Montreal Quebec
Canada McGill University Montreal Quebec

Sponsors (2)

Lead Sponsor Collaborator
Eli Lilly and Company AurKa Pharma Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1: Maximum Tolerated Dose Maximum Tolerated Dose (MTD) was defined as the dose immediately below the dose at which =2/3, =2/6, or =3/9 participants in a cohort experienced a dose limiting toxicity (DLT) during the first 21 days of treatment (Cycle 1) in Phase 1. Cycle 1 (21 days)
Primary Phase 2: Percentage of Participants Who Achieved Partial Response (PR) or Complete Response (CR) [Objective Response Rate (ORR)] Objective response rate (ORR) was defined as a percentage of responders who achieved complete response or partial response (CR+PR) as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1). Complete response (CR) is defined as disappearance of all target (and non-target) lesions, and no appearance of new lesion. Partial response (PR) was defined as at least a 30% decrease in the sum of longest diameters (LD) of target lesions, taking as reference the baseline sum of LD, no progression of non-target lesions, and no appearance of new lesions. Baseline to Objective Disease Progression (Up to 11 months)
Secondary Phase 1: Number of Participants With One or More Treatment-Emergent Adverse Events A treatment-emergent adverse event (AE) is an AE that started or worsened (increased in severity) from the treatment start date to 30 days after the treatment end date. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section. Cycle 1 Day 1 through 30 Days After Treatment End Date (Up to 29 Months)
Secondary Phase 2: Number of Participants With One or More Treatment-Emergent Adverse Events A treatment-emergent adverse event (AE) is an AE that started or worsened (increased in severity) from the treatment start date to 30 days after the treatment end date. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section. Cycle 1 Day 1 through 30 Days After Treatment End Date (Up to 29 Months)
Secondary Phase 2: Pharmacokinetic (PK): Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post-dose (AUC[0-12]) (Phase 2) Area under the plasma concentration-time curve for LY3295668 from time zero to 12 hours. Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8 - 12 hours postdose; Cycle 1: Day 2 and Day 8 predose
Secondary Phase 2: PK: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Post-dose (AUC[0-24]) Area under the plasma concentration-time curve for LY3295668 from time zero to 24 hours. Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8-12 hours post-dose; Cycle 1: Day 2 and Day 8 Predose
Secondary Phase 2: PK: Maximum Observed Plasma Concentration (Cmax) Maximum observed plasma concentration for LY3295668. Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8 hours post-dose
Secondary Phase 2: PK: Time of Maximum Observed Plasma Concentration (Tmax) Time of maximum observed plasma concentration of LY3295668. Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8 hours post-dose
Secondary Phase 2: PK: Apparent Terminal Elimination Half-life (t1/2) Apparent terminal elimination half-life of LY3295668. Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8-12 hours post-dose; Cycle 1: Day 2 and Day 8 Predose
Secondary Phase 2: PK: Apparent Total Plasma Clearance (CL/F) Apparent total plasma clearance of LY3295668. Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8 -12 hours post-dose; Cycle 1: Day 2 and Day 8 Predose
Secondary Phase 2: PK: Apparent Volume of Distribution (Vz/F) Apparent volume of distribution of LY3295668. Cycle 1: Day 1 and Day 15: Predose, 1, 2, 4, 6, and 8 -12 hours post-dose; Cycle 1: Day 2 and Day 8 Predose
Secondary Phase 1: Number of Participants With Worst Post-Baseline Grade >=3 White Blood Cell Count (WBC) Presented are participants with the worst post-baseline WBC Grade >= 3 using the National Cancer Institute (NCI) Common Terminology Criteria For Adverse Events version 4.03 (CTCAE v4.03). where Grade 1: < Lower Limit Normal (LLN) - 3000/mm3; Cycle 1 Day 1 through 30 Days After Treatment End Date (Up to 29 Months)
Secondary Phase 1: Number of Participants With Worst Post-Baseline Grade >=3 Neutrophils (Segmented and Blended) Presented are participants with the worst post-baseline neutrophils Grade >=3 using the NCI-CTCAE v4.03 where Grade 1: < LLN - 1500/mm3; Cycle 1 Day 1 through 30 Days After Treatment End Date (Up to 29 Months)
Secondary Phase 1: Number of Participants With Worst Post-Baseline Grade >=3 Lymphocytes Presented are participants with the worst post-baseline lymphocytes Grade >=3 using the NCI-CTCAE version 4.03 where Grade 1: Cycle 1 Day 1 through 30 Days After Treatment End Date (Up to 29 Months)
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT03190811 - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors Phase 1/Phase 2